Drug Profile


Alternative Names: SR 57667; SR 57667B

Latest Information Update: 02 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Antidementias; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 02 Oct 2007 Discontinued - Phase-II for Alzheimer's disease in France (PO)
  • 02 Oct 2007 Discontinued - Phase-II for Parkinson's disease in France (PO)
  • 15 Aug 2006 This compound is still in active development for Alzheimer's and Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top